EU Patent EP 4 273 231 A1 · US Patent Pending

The Only Patented Protocol
for Canine & Feline Platelet Concentrate

Achieve 5× platelet concentration from just 4.5 mL of blood. Built for both dogs and cats. No proprietary kits. 80% lower cost per procedure. Dual patent protection across EU and USA.

Concentration
80% Lower Cost
38 EPO States

Science at the Service of Animal Health

PlatGen is a university spin-off of the Universidade de Trás-os-Montes e Alto Douro (UTAD), created to commercialise a breakthrough platelet concentrate (PC) protocol for veterinary regenerative medicine — explicitly validated for both canines and felines.

Our patented double-centrifugation method produces platelet concentrates with approximately 5× the concentration of whole blood baseline, using only 4.5 mL of blood and standard laboratory consumables — no proprietary kits required. This outperforms every commercial system described in the scientific literature for dogs and cats.

We hold a granted European Patent (EP 4 273 231 A1, valid in 38 EPO contracting states) and a pending US patent application (US 2025/0223557 A1, PCT/IB2023/054555, national phase entry September 2024).

Science-First

Built on peer-reviewed research and validated haematological data published by UTAD veterinary researchers.

Canine & Feline-First

The only protocol designed, validated and patented specifically for dogs and cats — the most underserved species in veterinary regenerative medicine.

No Kit Dependency

Standard laboratory consumables only. No proprietary kits, no locked supply chains, no recurring license fees.

Dual Patent Protection

EU patent valid in 38 states. US patent pending. The two largest veterinary markets in the world, covered.

EP 4 273 231 A1 · US 2025/0223557 A1

The PlatGen Protocol

A two-spin centrifugation method that recovers approximately 5× platelet concentration from whole blood baseline — in any clinical or research setting for dogs and cats.

1
Blood Collection
4.5 mL citrated whole blood from jugular vein
2
1st Centrifugation
200–500 g · 4–10 min
Separates plasma from RBCs
3
Plasma Recovery
Careful pipetting at 45–80°
Maximum yield, no contamination
4
2nd Centrifugation
400–900 g · 5–15 min
Plasma divided into 3 fractions
5
Platelet Concentrate
Bottom fraction collected
Ready to use
Validated Haematological Results — Canine & Feline PC Whole Blood (baseline) PlatGen PC
Platelets PLT (×10³/mL) 297.50 (149.0–340.8) 1,492.00 (890–1,791)
Erythrocytes RBC (×10⁶/mL) 8.65 (8.12–9.39) 1.20 (0.66–1.44)
Leucocytes WBC (×10³/mL) 7.88 (5.41–9.05) 4.01 (2.55–6.58)
Concentration Factor ~5× baseline

Source: Clemente Pires et al. (2022). EP 4 273 231 A1. European Patent Office. Values expressed as median (interquartile range).

Osteoarthritis Corneal Ulcers & Keratitis Chronic Skin Wounds Gingivostomatitis (FCGS) Bone Regeneration FBS Substitute (Biotech)

"For the first time, a protocol achieves ~5× platelet concentration specifically validated in both dogs and cats — outperforming all commercial systems described in veterinary literature, from only 4.5 mL of blood."

A Growing Market. A Critical Gap.

Veterinary regenerative medicine is expanding rapidly. Yet the canine and feline segment — the fastest-growing — has no validated, patented product.

$345M
Global vet regenerative medicine (2024)
12.9%
Canine & feline segment CAGR (2025–2032)
160M+
Dogs & Cats in the USA (2025)

EU Market

  • Market valued at USD 90.9–147M in 2024 · CAGR 8.9–15.8% to 2031/2032
  • Veterinary PRP applications grew 12% in 2024 YoY
  • Canine & feline segment: highest projected CAGR in Europe
  • Germany: largest EU market share

US Market

  • USD 97.8–108M (2024) · CAGR 11.5% to 2033
  • 160M+ dogs and cats — pet ownership rapidly increasing across US households
  • FDA precedent (April 2024): PRP products commercialisable under risk-based decision — no formal pre-market approval required
  • USD 39.8B spent on veterinary care in the USA in 2024
NO VALIDATED CANINE & FELINE PRODUCT EXISTS

VetStem's PrecisePRP Canine (the only FDA-reviewed PRP product):

  • Designed for dogs · Not validated for cats
  • Platelet concentration: 500K PLT/µL

PlatGen:

  • Specifically validated in both dogs and cats · Patent pending (US)
  • Platelet concentration: 1,492K PLT/µL
That is 3× higher concentration,
in the species the market has forgotten.

The Inventors

MC

Maria dos Anjos Clemente Pires

Principal Investigator
"Lead inventor. Specialisation in veterinary medicine and platelet products."
CS

Carla Sofia Alves Soares

Researcher
"Co-author, Soares et al. 2021 (Trends in Biotechnology). Platelet-derived products in veterinary medicine."
SF

Susana Margarida Ferreira de Sá Faria

Researcher
"Protocol development and centrifugation optimisation."
PC

Pedro Miguel Pires de Carvalho

Researcher
"Multiple peer-reviewed publications in veterinary regenerative medicine."

Intellectual Property

European Patent

EP 4 273 231 A1

"Method to Produce Mammal Platelet Concentrate, Mammal Platelet Concentrate and Use Thereof"
Published 8 November 2023
Valid in 38 EPO Contracting States
Status GRANTED

US Patent Application

US 2025/0223557 A1

Same invention · PCT/IB2023/054555
Published 10 July 2025
Appl. No. 18/851,575
Status PENDING — examination in progress

UTAD

Spin-off of the Universidade de Trás-os-Montes e Alto Douro
Vila Real · Portugal

Join PlatGen

Whether you are a veterinary clinic, an investor, or an industry partner — we want to hear from you.

Implement the PlatGen protocol for dogs and cats in your practice. Early adopter access available in EU and US.

Request Protocol Info

Seed round open · €750K · Dual-market IP. University spin-off. Peer-reviewed science for canines and felines.

Request Investor Deck

OEM licensing, research partnerships, and clinical validation collaborations with leading industry players.

Explore Partnerships